LCM
TRDA icon

Lynx1 Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Lynx1 Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
178,606
-33,083
-16% -$317K 0.15% 13
2026
Q1 		$2.67M Buy
211,689
+160,000
+310% +$1.83M 0.42% 13
2025
Q4 		$531K Buy
+51,689
New +$436K 0.11% 17

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Lynx1 Capital Management's TRDA Position: Q2 2026 in Review

Lynx1 Capital Management reduced its Entrada Therapeutics (TRDA) stake by 16% in Q2 2026, selling an estimated $317K and leaving 178,606 shares worth $1.31M. The position accounts for 0.15% of the portfolio, ranked #13.

Lynx1 Capital Management first reported a position in TRDA in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.67M in Q1 2026. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Lynx1 Capital Management held 178,606 shares of Entrada Therapeutics worth $1.31M as of Q2 2026.
  • Lynx1 Capital Management sold 33,083 Entrada Therapeutics shares in Q2 2026, an estimated $317K.
  • Entrada Therapeutics made up 0.15% of Lynx1 Capital Management's portfolio in Q2 2026, its #13 holding.
  • Lynx1 Capital Management first reported a position in Entrada Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Lynx1 Capital Management's Entrada Therapeutics position peaked at $2.67M in Q1 2026.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.